Press release
Hemophilia A Market is expected to show positive growth, during the forecast period of 2019 to 2032, DelveInsight
Hemophilia A Market Insights report from DelveInsight provides a thorough understanding of the Hemophilia A Market size by treatment, epidemiology, emerging therapies, market share of the various therapies, and the current and forecasted Hemophilia A Market size from 2019 to 2032 divided into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan) regions.Key highlights of the Hemophilia A Market Research Report
• According to DelveInsight, the Hemophilia A Market in 7MM is expected to witness a major change in the study period 2019-2032
• About 30% of severe Hemophilia A patients develop neutralizing anti-FVIII alloantibodies (inhibitors), which render the FVIII replacement ineffective. The standard of care therapy for patients with inhibitors is to induce immune tolerance with high-dose, high-frequency FVIII and treatment with bypassing agents (e.g., recombinant activated factor VII such as NovoSeven, FEIBA).
• DelveInsight's analysis estimates that the Hemophilia A treatment hemisphere is mainly driven by non-inhibitors drug candidates as the development of Hemophilia A gene therapies are mainly focussed on non-inhibitors segment.
• The Hemophilia A treatment market landscape is shifting towards extended half-life therapies as well as novel approaches, including siRNA, bispecific antibodies, and Hemophilia A gene therapy.
Download Sample Report- https://www.delveinsight.com/sample-request/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Hemophilia A Overview
Hemophilia is a group of bleeding disorders. A congenital deficiency of certain clotting factors causes Hemophilia and the main form of Hemophilia is Hemophilia A and is due to the deficiency of factor VIII.
Hemophilia A Epidemiology Insights
Over 80% of the total patient pool of Hemophilia has Hemophilia A. The total Hemophilia A prevalent population in the7MM in 2020 was 43,243. The prevalence is further expected to rise by 2030, during the study period (2018-2030). On the basis of severity, the Hemophilia A cases can be segmented in to mild, moderate and severe. Severe Hemophilia A cases are more prominent in comparison to mild and moderate. Additionally, moderate and severe accounts for 75% of the Hemophilia A patient pool.
Hemophilia A Epidemiology Segmentation in the 7MM
• Total Diagnosed Hemophilia A Prevalent Pool
• Severity-specific Hemophilia A Prevalent Pool
• Inhibitor-specific Hemophilia A Prevalent Pool
• Total Treated Hemophilia A Prevalent Pool
Do you have want to know more information related to report? If yes, visit here- https://www.delveinsight.com/report-store/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Hemophilia A Therapeutics Market Landscape
The Hemophilia A treatment landscape provides "On Demand" and "Prophylaxis" treatment options to the patients. However, the Prophylaxis treatment option has gained much absorption in the market as compared to the On-demand treatment option.
Hemophilia A Market
The present Hemophilia A therapy market offers Factor Replacement Concentrates, and Bypassing agents as major treatment options. The market has several recombinant factor VIII (FVIII) products available with high specific activities. Plasma-derived clotting factors products are also present in the Hemophilia A treatment market. Furthermore, in adjunctive therapies, antifibrinolytic and supportive measures, which include icing, immobilization and others are also available. Besides, the market presence of approved treatment regimes, off-label products are also available for Hemophilia A.
Hemophilia A Treatment Market
The treatment consists of replacing the missing clotting protein (factor VIII) and preventing the complications associated with the disorder. Replacement of this protein may be obtained through recombinant factor VIII, which is artificially created in a lab. Several recombinant forms of factor VIII are also approved for in the Hemophilia A treatment market.
Hemophilia A Marketed Therapies
• Jivi (formerly BAY94-9027): Bayer
• Hemlibra (Emicizumab-kxwh): Roche (Chugai/ Genentech)
• Esperoct (N8-GP; Turoctocog alfa pegol): Novo Nordisk
• Sevenfact [coagulation factor VIIa (recombinant)-jncw]: HEMA Biologics/LFB Pharmaceuticals, and several others
Hemophilia A Market Forecast
To bridge the gap, and meet the unmet needs in the Hemophilia A market domain, the scientific community, academia, and pharmaceutical companies are actively, and collaboratively seeking novel approaches, taking advantage of advanced technologies, and developing new pipeline therapies.
Scope of the Hemophilia A Market Report
• Study Period- 2019-2032
• Coverage- The United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), Japan
• Hemophilia A Market Companies- Bayer, Roche (Chugai/ Genentech), Novo Nordisk, HEMA Biologics/LFB Pharmaceuticals, and several others
• Hemophilia A Therapies- Jivi (formerly BAY94-9027), Hemlibra (Emicizumab-kxwh), Esperoct (N8-GP; Turoctocog alfa pegol), Sevenfact [coagulation factor VIIa (recombinant)-jncw], and several others
Request Sample Report- https://www.delveinsight.com/sample-request/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Hemophilia A Executive Summary
3. Competitive Intelligence Analysis
4. Hemophilia A Market Overview at a Glance
5. Hemophilia A Disease Background and Overview
6. Patient Journey
7. Hemophilia A Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Hemophilia A Unmet Needs
10. Key Endpoints of Hemophilia A Treatment
11. Hemophilia A Marketed Products
12. Hemophilia A Emerging Therapies
13. Hemophilia A: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Hemophilia A Market Outlook
16. Hemophilia A Access and Reimbursement Overview
17. KOL Views
18. Hemophilia A Market Drivers
19. Hemophilia A Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Hemophilia A Market Report Scope
• The report covers the descriptive overview of Hemophilia A, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Hemophilia A epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Hemophilia A is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Hemophilia A market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hemophilia A market
Why should you buy this report?
• The report will help in developing business strategies by understanding trends shaping and driving the Hemophilia A market
• To understand the future market competition in the Hemophilia A market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Hemophilia A in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Hemophilia A market
• To understand the future market competition in the Hemophilia A market
Do you have any query related to report? if yes, visit here- https://www.delveinsight.com/report-store/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Contact Us
Yash
info@delveinsight.com
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hemophilia A Market is expected to show positive growth, during the forecast period of 2019 to 2032, DelveInsight here
News-ID: 2722551 • Views: …
More Releases from DelveInsight Business Research

Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…

Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,…

Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,…

Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Hemophilia
Rising Occurrence Of Genetic Abnormalities Fuels Hemophilia Market Growth: Stren …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
What Is the Expected CAGR for the Hemophilia Market Through 2025?
In recent times, there has been a significant expansion in the hemophilia market. The market, which stood at $13.83 billion in 2024, is projected to inflate to $15.13 billion in 2025, exhibiting a compound annual growth rate (CAGR)…
Global Hemophilia Market Size & Trends
According to a new market research report published by Global Market Estimates, the global hemophilia market is projected to grow at a CAGR of 6.8% from 2023 to 2028.
During the forecast period, the global hemophilia market is anticipated to experience growth due to advancements in medical research, an increase in hemophilia incidence, and rising awareness and diagnosis.
Browse 147 Market Data Tables and 115 Figures spread through 163 Pages and…
Acquired Hemophilia Treatment Market - Embracing Hope, Defying Hemophilia: Trans …
Newark, New Castle, USA: The "Acquired Hemophilia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Acquired Hemophilia Treatment Market: https://www.growthplusreports.com/report/acquired-hemophilia-treatment-market/7748
This latest report researches the industry structure,…
Hemophilia Market
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand…
Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Koval …
ReportsWorldwide has announced the addition of a new report title Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement , Immune Tolerance Induction ) Outlook 2022 to its growing collection of premium market research reports.
Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged…
In-depth analysis of the Global Hemophilia Market: hemophilia A, hemophilia B, h …
Latest industry research report on: Global Hemophilia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/1064504
The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes…